BHC vs COO

For growth investors, Bausch Health Companies Inc.

(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus 5. 1% for The Cooper Companies, Inc. (COO). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 3x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bausch Health Companies Inc.

(BHC) is the cheapest at 13. 3x versus The Cooper Companies, Inc. at 32. 7x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x.

Over the past 5 years, The Cooper Companies, Inc.

(COO) delivered a total return of -39. 5%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: COO returned +57. 9% versus BHC's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Cooper Companies, Inc.

(COO) is the lower-risk stock at 0. 93β versus Bausch Health Companies Inc. 's 1. 02β — meaning BHC is approximately 9% more volatile than COO relative to the S&P 500. On balance sheet safety, The Cooper Companies, Inc. (COO) carries a lower debt/equity ratio of 34% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bausch Health Companies Inc.

(BHC) is pulling ahead at 8. 5% versus 5. 1% for The Cooper Companies, Inc. (COO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -4. 6% for The Cooper Companies, Inc.. Over a 3-year CAGR, BHC leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Cooper Companies, Inc.

(COO) is the more profitable company, earning 9. 2% net margin versus 1. 5% for Bausch Health Companies Inc. — meaning it keeps 9. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BHC leads at 21. 3% versus 16. 7% for COO. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bausch Health Companies Inc.

(BHC) trades at 1. 3x forward P/E versus 13. 2x for The Cooper Companies, Inc. — 11. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COO: 53. 6% to $93. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, The Cooper Companies, Inc.

(COO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93)). Both have compounded well over 10 years (COO: +57. 9%, BHC: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BHC is a small-cap deep-value stock; COO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.